Skip to content

In the BioHarmony Drug Report Database

Tagraxofusp

Elzonris (tagraxofusp) is a protein pharmaceutical. Tagraxofusp was first approved as Elzonris on 2018-12-21. It is used to treat malignant histiocytic disorders in the USA. It has been approved in Europe to treat lymphoma.
Trade Name Elzonris
Common Name Tagraxofusp
Indication lymphoma, malignant histiocytic disorders
Drug Class Fusion proteins
Tagraxofusp
Get full access now